Home › Research › Treatments
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H. Weinreb, Leslie J. Williams, Marcel Maier, Robert W. Dunstan, Stephen Salloway et al.. Nature, 2016-08-30
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This study reported the generation of aducanumab, a human monoclonal antibody designed to selectively target aggregated Aβ. In a transgenic mouse model of AD, aducanumab entered the brain, bound parenchymal Aβ, and reduced both soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions reduced brain Aβ and was accompanied by a slowing of clinical decline.
What this study adds
Evidence grade: Low
Reports that the antibody aducanumab reduces amyloid-beta plaques in Alzheimer's disease. Clearing plaques is a change in brain pathology, and this record does not state whether thinking or daily functioning improved with it.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L. J., Maier, M., et al. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. https://doi.org/10.1038/nature19323
Vancouver
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams LJ, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016. doi:10.1038/nature19323. PMID: 27582220.
BibTeX
@article{sevigny2016-27582220,
author = {Sevigny, Jeff and Chiao, Ping and Bussière, Thierry and Weinreb, Paul H. and Williams, Leslie J. and Maier, Marcel and Dunstan, Robert W. and Salloway, Stephen and others},
title = {{The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease}},
journal = {Nature},
year = {2016},
doi = {10.1038/nature19323},
pmid = {27582220},
url = {https://doi.org/10.1038/nature19323}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Aducanumab is a human monoclonal antibody that selectively targets aggregated Aβ.
- In a transgenic mouse model of AD, aducanumab enters the brain, binds parenchymal Aβ, and reduces soluble and insoluble Aβ in a dose-dependent manner.
- In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner.
- The reduction in brain Aβ is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores.
- The main safety and tolerability findings are amyloid-related imaging abnormalities.
Why it matters
Reports that the antibody aducanumab reduces amyloid-beta plaques in Alzheimer's disease. Clearing plaques is a change in brain pathology, and this record does not state whether thinking or daily functioning improved with it.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 60/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 3,050 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 254.2 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 6 / 6 | Cited 183.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 5 / 6 | Cited by 149 other studies in this library |
| Still being cited | 4 / 4 | Cited 901 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Alfred W. Sandrock: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Zurich: institution h-index 1,220 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27582220) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
149 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.